trending Market Intelligence /marketintelligence/en/news-insights/trending/_qytuidkcuadl9mwvyednq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Ziopharm study of CAR-T therapy in blood cancer put on clinical hold by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Ziopharm study of CAR-T therapy in blood cancer put on clinical hold by US FDA

The U.S. Food and Drug Administration has placed a clinical hold on ZIOPHARM Oncology Inc.'s phase 1 study using CAR-T therapies to treat certain types of blood cancers.

Chimeric antigen receptor T-cell, or CAR-T cell, therapies involve infusing patients with lab-enhanced versions of their own cells to attack cancer cells.

The trial is being conducted by Ziopharm, Intrexon Corp.'s unit Precigen Inc. and the University of Texas MD Anderson Cancer Center in patients with CD19 positive leukemias and lymphomas that have returned or are resistant to treatment.

Leukemia is a type of cancer that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Lymphoma is a type of cancer that begins in cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow and other parts of the body.

The FDA has requested additional information relating to chemistry, manufacturing and controls. The company, along with its partners, will address the FDA's requests, which may cause a delay in the initiation of this trial.

"We know what is needed to address the hold issues and are looking forward to responding to the agency in a timely manner," said Ziopharm CEO Laurence Cooper.

Boston-based Ziopharm Oncology is a biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer.